Nebivolol Stada

Nebivolol, the active ingredient in Nebivolol Stada, is a beta blocker presented as an oral tablet for oral use. It is used to treat hypertension and heart failure in adult patients. GNH USA supplies Nebivolol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is indicated for conditions within the cardiovascular disease spectrum where beta‑adrenergic blockade is beneficial.

Hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk. Heart failure: improves left‑ventricular function and decreases hospitalization rates in patients with chronic heart failure.

Nebivolol may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness: especially on standing. - Fatigue: general tiredness or reduced energy. - Nasal congestion: mild obstruction of nasal passages. - Diarrhoea: loose stools without blood. - Bradycardia: heart rate below normal resting levels.

Serious or Rare Side Effects: - Severe bradycardia: may require medical intervention. - Acute heart failure exacerbation: worsening of cardiac symptoms. - Bronchospasm: difficulty breathing, particularly in asthmatic patients. - Hypotension: dangerously low blood pressure. - Allergic reactions: rash, itching, or swelling. - Liver enzyme elevation: abnormal liver function tests.

When prescribing Nebivolol, clinicians should consider several safety measures to minimise risk.

Monitor blood pressure: adjust therapy based on response. Assess cardiac function: use caution in severe heart failure. Avoid abrupt discontinuation: taper to prevent rebound hypertension. Use with caution in asthma or COPD: beta‑1 selectivity may still affect beta‑2 receptors. Store at room temperature: keep in the original pack, protect from moisture.

Nebivolol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Combined with other beta blockers: risk of excessive bradycardia. - Potent CYP2D6 inhibitors (e.g., paroxetine, quinidine): may increase plasma concentrations. - Calcium channel blockers (verapamil, diltiazem): may enhance negative inotropic effect.

Moderate Interactions (Monitor Closely): - NSAIDs: may attenuate antihypertensive effect. - Diuretics: may increase risk of hypotension. - Insulin or oral hypoglycemics: may mask hypoglycaemia symptoms.